Moleculin Biotech (MBRX)
(Real Time Quote from BATS)
$4.41 USD
+0.06 (1.38%)
Updated Apr 25, 2024 02:23 PM ET
After-Market: $4.30 -0.11 (-2.49%) 4:10 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Moleculin Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 43 | 71 | 15 | 11 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 2 | 2 | 3 |
Total Current Assets | 26 | 46 | 73 | 17 | 13 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 11 | 11 | 11 | 11 | 11 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 38 | 57 | 84 | 29 | 25 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 5 | 4 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 5 | 4 | 3 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 0 | 1 | 8 | 6 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 12 | 5 | 5 | 11 | 10 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 158 | 154 | 152 | 75 | 55 |
Retained Earnings | -132 | -102 | -73 | -57 | -40 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 26 | 52 | 79 | 18 | 16 |
Total Liabilities & Shareholder's Equity | 38 | 57 | 84 | 29 | 25 |
Total Common Equity | 26 | 52 | 79 | 18 | 16 |
Shares Outstanding | 2.20 | 1.90 | 1.90 | 0.60 | 0.50 |
Book Value Per Share | 11.85 | 27.47 | 41.57 | 29.60 | 31.14 |
Fiscal Year End for Moleculin Biotech, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 24 | 25 | 32 | 37 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 3 | 3 | 3 | 2 |
Total Current Assets | NA | 26 | 28 | 35 | 39 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 11 | 11 | 11 | 11 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 38 | 40 | 47 | 51 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 4 | 7 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 7 | 4 | 7 | 5 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 12 | 4 | 7 | 5 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 158 | 156 | 156 | 155 |
Retained Earnings | NA | -132 | -121 | -116 | -110 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 26 | 35 | 40 | 46 |
Total Liabilities & Shareholder's Equity | NA | 38 | 40 | 47 | 51 |
Total Common Equity | 0 | 26 | 35 | 40 | 46 |
Shares Outstanding | 2.20 | 2.20 | 1.90 | 1.90 | 1.90 |
Book Value Per Share | 0.00 | 11.85 | 18.49 | 21.19 | 24.04 |